SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

180 Life Sciences Corp.

(Name of Issuer)

Common Stock, \$0.0001 par value

(Title of Class of Securities)

68236V302

(CUSIP Number)

04/09/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 68236V302				
1	Names of Reporting Persons			
	AMTRUST FINANCIAL SERVICES, INC.			
2	Check the appropriate box if a member of a Group (see instructions) (a) (b)			
3	Sec Use Only			
4	Citizenship or Place of Organization			
-	DELAWARE			

Number of Shares Benefici ally Owned by Each Reporti	5	Sole Voting Power			
		509,707.00			
	6	Shared Voting Power			
		0.00			
	7	Sole Dispositive Power			
ng Person		509,707.00			
With:	8	Shared Dispositive Power			
	0	0.00			
	Aggregate Amount Beneficially Owned by Each Reporting Person				
9	509,707.00				
	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)				
10					
	Percent of class represented by amount in row (9)				
11	9.8 %				
12	Type of Reporting Person (See Instructions)				
12	со				

SCHEDULE 13G

CUSIP No.

68236V302

	Nama a				
1	Names of Reporting Persons				
	AMTRUST INTERNATIONAL UNDERWRITERS DAC				
2	Check the appropriate box if a member of a Group (see instructions)				
	(a)				
3	Sec Use Only				
4	Citizenship or Place of Organization				
	IRELAND				
		Sole Voting Power			
	5	0.00			
Number of					
Shares Benefici	6	Shared Voting Power			
ally Owned		509,707.00			
by Each Reporti	_	Sole Dispositive Power			
ng Person	7	0.00			
With:		Shared Dispositive Power			
	8	509,707.00			
	Aggregate Amount Beneficially Owned by Each Reporting Person				
9	509,707.00				
	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)				
10					
ı.		I			

11	Percent of class represented by amount in row (9)
	9.8 %
12	Type of Reporting Person (See Instructions)
	IC

SCHEDULE 13G

Item 1.

(a) Name of issuer:

180 Life Sciences Corp.

(b) Address of issuer's principal executive offices:

3000 EL CAMINO REAL, BLDG 4, STE 200 Palo Alto, CA, 94306

Item 2.

(a) Name of person filing:

The persons filing this statement are AmTrust Financial Services, Inc. ("AFSI") and AmTrust International Underwriters DAC ("AIUDAC", together with AFSI, the "Reporting Persons"). AFSI has the sole voting and dispositive power with regard to 509,707 of the issuer's shares of common stock. AIUDAC is a subsidiary of AFSI.

(b) Address or principal business office or, if none, residence:

The principal business address of the AFSI is 59 Maiden Lane, 43rd Floor, New York, NY 10038. The registered address of AIUDAC is 6-8 College Green, Dublin 2, D02 VP48.

(c) Citizenship:

AFSI is incorporated in Delaware. AIUDAC is incorporated in Ireland.

(d) Title of class of securities:

Common Stock, \$0.0001 par value

(e) CUSIP No.:

68236V302

- Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
 - (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
 - (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
 - (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
 - (d) 📃 Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
 - (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
 - (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
 - (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
 - (h) 📃 A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
 - (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
 - (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
 - (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

(a) Amount beneficially owned:

AFSI has the sole voting and dispositive power with regard to 509,707 of the issuer's shares of common stock and is acting as an advisor on behalf of AIUDAC. AIUDAC is a subsidiary of AFSI.

(b) Percent of class:

As of April 9, 2025, the Reporting Persons may be deemed to beneficially own in the aggregate 509,707 of the issuer's shares of common stock, representing approximately 9.8% of the issuer's outstanding shares (based on 5,185,780, shares outstanding as of March 31, 2025, as disclosed in the issuer's Annual Report on Form 10-K for the year ended December 31, 2024.) %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

The information set forth on the cover pages hereto and Item 4(a) is hereby incorporated in its entirety herein.

(ii) Shared power to vote or to direct the vote:

The information set forth on the cover pages hereto and Item 4(a) is hereby incorporated in its entirety herein.

(iii) Sole power to dispose or to direct the disposition of:

The information set forth on the cover pages hereto and Item 4(a) is hereby incorporated in its entirety herein.

(iv) Shared power to dispose or to direct the disposition of:

The information set forth on the cover pages hereto and Item 4(a) is hereby incorporated in its entirety herein.

- Item 5. Ownership of 5 Percent or Less of a Class.
- Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

AMTRUST FINANCIAL SERVICES, INC.

Signature:/s/ Stephen UngarName/Title:Executive Vice President, General CounselDate:04/16/2025

AMTRUST UNDERWRITERS DAC INTERNATIONAL

Signature:/s/ Peter FarrellName/Title:Company DirectorDate:04/16/2025

Exhibit Information

99.1 - Joint Filing Agreement

EXHIBIT 99.1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing the attached Schedule 13G (or any amendments thereto) relating to the common stock of 180 Life Sciences Corp. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of April 16, 2025.

AmTrust Financial Services, Inc.

By: /s/ Stephen Ungar Name: Stephen Ungar Title: Executive Vice President, General Counsel

AmTrust International Underwriters DAC

By: <u>/s/ Peter Farrell</u> Name: Peter Farrell Title: Company Director